CKD-706
Phase 1Small molecule
Chong Kun Dang PharmaceuticalCKD-706 is one of 41 small molecule programs targeting Immunogenicity. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
98 competitors in Immunogenicity
#DrugCompanyPhaseTrials
1Perjeta
RochePhase 3
Rabies Vaccine
NovartisPhase 3
Prolia
OOrganon and Co
Phase 3
Rsvpref
PfizerPhase 3
HPV Vaccine
SShanghai Zerun Biotechnology Co.,Ltd
Phase 3
PCV21
SanofiPhase 3
Bexsero
GSKPhase 3
Gardasil-9
BBeijing Health Guard Biotechnology, Inc
Phase 3
Opfolda
Johnson & JohnsonPhase 3
Gardasil
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CKD-706. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details